Surgery Partners
SGRYNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $26.73 Prior regular-session close from the quote source.
- $26.39–$26.70 Regular-session low and high so far today.
- 2.6M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $11.41–$27.23 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own SGRY if Surgery Partners is a levered outpatient-surgery network whose equity value depends on converting the secular shift from hospitals to ambulatory surgical facilities into parent-level cash earnings, not just larger reported revenue.
SGRY price history
Loading recent earnings…
Investment thesis
What must happen next
The outpatient migration of surgical procedures continues to feed Surgery Partners’ owned and operated facility network because physicians, payers, and patients keep finding ambulatory settings attractive versus hospitals; needs calibration: same-facility case-volume and revenue-per-case disclosures would set the precise break.StrengtheningMateriality: High
Item 1 Business description says Surgery Partners owns and operates a national network of surgical facilities and ancillary services. If this holds, the company has a structural demand tailwind; if it breaks, revenue growth becomes acquisition-dependent and less valuable.
Watch: Large hospital systems retain or recapture surgical specialists through employment models and direct case flow back to hospital outpatient departments.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 Business description says Surgery Partners owns and operates a national network of surgical facilities and ancillary services.
Open source ↗Local facility density, ancillary services, and operating discipline allow Surgery Partners to absorb labor, supply, and reimbursement pressure rather than letting growth become low-quality volume; needs calibration: the data provided do not include same-facility margin or wage/supply inflation.HoldingMateriality: High
GAAP annual operating income increased from $302.2 million in FY2021 to $389.5 million in FY2025. Revenue growth only creates value if the company keeps enough of each incremental case after clinical staffing, supplies, and payer friction.
Watch: Nurse, anesthesiology, and surgical technician shortages force sustained wage increases that cannot be passed through to payers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income increased from $302.2 million in FY2021 to $389.5 million in FY2025.
Open source ↗Surgical-center billing and collections remain cash-converting enough to fund growth and service obligations despite GAAP losses.StrengtheningMateriality: Medium
GAAP annual operating cash flow was positive in FY2022, FY2023, FY2024, and FY2025. Positive operating cash flow gives the company room to invest and manage leverage; weak cash conversion would turn the roll-up model into a financing problem.
Watch: Commercial payers or Medicare Advantage plans slow payments, increase denials, or require more prior authorizations for outpatient procedures.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was positive in FY2022, FY2023, FY2024, and FY2025.
Open source ↗Acquisition-led network expansion remains financeable only if leverage and refinancing costs do not capture the cash generated by the facilities before it reaches common shareholders.WeakeningMateriality: Medium
Liabilities increased from $3.7412 billion at FY2022 year-end to $4.9884 billion at FY2025 year-end. This is the key equity-risk claim: the business can grow while the common stock still disappoints if debt service absorbs the improvement.
Watch: Credit markets demand materially higher refinancing costs or tighter covenants for Surgery Partners’ debt.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Liabilities increased from $3.7412 billion at FY2022 year-end to $4.9884 billion at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The outpatient migration of surgical procedures continues to feed Surgery Partners’ owned and operated facility network because physicians, payers, and patients keep finding ambulatory settings attractive versus hospitals; needs calibration: same-facility case-volume and revenue-per-case disclosures would set the precise break. If this holds, the company has a structural demand tailwind; if it breaks, revenue growth becomes acquisition-dependent and less valuable.
Local facility density, ancillary services, and operating discipline allow Surgery Partners to absorb labor, supply, and reimbursement pressure rather than letting growth become low-quality volume; needs calibration: the data provided do not include same-facility margin or wage/supply inflation. Revenue growth only creates value if the company keeps enough of each incremental case after clinical staffing, supplies, and payer friction.
Surgical-center billing and collections remain cash-converting enough to fund growth and service obligations despite GAAP losses. Positive operating cash flow gives the company room to invest and manage leverage; weak cash conversion would turn the roll-up model into a financing problem.
Acquisition-led network expansion remains financeable only if leverage and refinancing costs do not capture the cash generated by the facilities before it reaches common shareholders. This is the key equity-risk claim: the business can grow while the common stock still disappoints if debt service absorbs the improvement.
All standing thesis claims
Original report summary
Surgery Partners is a levered outpatient-surgery network whose equity value depends on converting the secular shift from hospitals to ambulatory surgical facilities into parent-level cash earnings, not just larger reported revenue.
Bull case and bear case
Bull case and bear case for Surgery Partners
Where the evidence on Surgery Partners disagrees: Mixed on the latest evidence (Nov 12, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
The outpatient migration of surgical procedures continues to feed Surgery Partners’ owned and operated facility network because physicians, payers, and patients keep finding ambulatory settings attractive versus hospitals; needs calibration: same-facility case-volume and revenue-per-case disclosures would set the precise break.
Local facility density, ancillary services, and operating discipline allow Surgery Partners to absorb labor, supply, and reimbursement pressure rather than letting growth become low-quality volume; needs calibration: the data provided do not include same-facility margin or wage/supply inflation.
Surgical-center billing and collections remain cash-converting enough to fund growth and service obligations despite GAAP losses.
Bear case: what the evidence questions
Acquisition-led network expansion remains financeable only if leverage and refinancing costs do not capture the cash generated by the facilities before it reaches common shareholders.
Thesis-Break Engine
Thesis-break watch · Surgery Partners
Loading the break-condition record for Surgery Partners.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Surgery Partners filed an SEC 8-K on 2026-11-09: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Surgery Partners filed an SEC 8-K on 2026-11-09: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Surgery Partners filed an SEC 8-K on 2026-10-26: Entered a material definitive agreement. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large hospital systems retain or recapture surgical specialists through employment models and direct case flow back to hospital outpatient departments.
- Nurse, anesthesiology, and surgical technician shortages force sustained wage increases that cannot be passed through to payers.
- Commercial payers or Medicare Advantage plans slow payments, increase denials, or require more prior authorizations for outpatient procedures.
- Credit markets demand materially higher refinancing costs or tighter covenants for Surgery Partners’ debt.
SGRY news
Loading headlines…
Financial statements
SGRY income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
SGRY: quick answers
- Which well-known investors own SGRY?
- 1 of the 37 well-known funds tracked here reported SGRY shares in their latest 13F filing. By share of the fund's portfolio: Oaktree Capital Management (Howard Marks), 0.2%. Fund portfolios
SGRY in well-known investors’ portfolios
1 of 37 funds reported SGRY shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Howard MarksOaktree Capital Management | 0.20% | $14.5M | New | Q2 2026 |
